ArticleThe journal of allergy and clinical immunology. Global2025
Allergy and dermatology US treatment guidelines review for adults with atopic dermatitis.
Article in The journal of allergy and clinical immunology. Global, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atopic dermatitis (AD) is a chronic, inflammatory condition that affects patients of all ages. Dermatologists and allergists often treat these patients, with each group of specialists following distinct sets of guidelines. Therefore, patients may receive different management depending on the specialist whom they consult. Objective: The goal of this article is to identify similarities and differences in the treatment of adults with AD using the most recent management guidelines in the United States put forth by the American Academy of Dermatology (AAD) and the American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters. Methods: The management guidelines for adults with AD from the American Academy of Dermatology and the American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters were reviewed to highlight similarities and differences. Results: We identified key similarities in the use of newer biologic agents, including dupilumab and tralokinumab. There are differences between the recommendations for topical phosphodiesterase-4 inhibitors, including crisaborole, and both topical and systemic Janus kinase inhibitors, including ruxolitinib, upadacitinib, abrocitinib, and baricitinib. Conclusion: This article highlights the fact that although the updated management guidelines for adults with AD in dermatology and allergy align on certain recommendations, notable differences that could influence clinical decision making remain. Despite both sets of guidelines being evidence-based, variations in recommendations arise when factoring in patient preferences, perspectives, and risk aversion. As newer treatments become available for patients with AD, it will be important to monitor the evolving concordance or discordance of these guidelines given their direct impact on patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.